HLA-A and neoplasm: To do this, we used a well-characterized HLA-A*02:01+ HPV-16+ tumor line, CaSki, as well as an autologous tumor cell line, HNSCC-56, generated through cellular reprogramming of primary tumor tissue as previously described (17) for in vitro cytotoxicity assays.